Transcatheter Aortic Valve Replacement (TAVR / TAVI)


New Option for Severe Aortic Stenosis

Surgical aortic valve replacement (AVR), is the gold standard for replacing the aortic valve for severe, symptomatic aortic stenosis. However, AVR is only available to patients who are healthy enough to undergo this type of surgery. That changed in late 2011 when the U.S. FDA approved the Edward’s SAPIEN Transcatheter Heart Valve Replacement (TAVR) procedure for patients who may have previously been deemed inoperable, turned down for surgery, because of other, serious health issues. 

Before the approval of TAVR, inoperable patients were limited to the option of being treated with medications or procedures to temporarily open their valves.